- Report
- April 2023
- 147 Pages
Global
From €5556EUR$5,999USD£4,661GBP
- Report
- April 2023
- 147 Pages
Global
From €5556EUR$5,999USD£4,661GBP
- Report
- October 2023
- 360 Pages
Global
From €3418EUR$3,690USD£2,867GBP
- Report
- May 2023
- 274 Pages
Global
From €3307EUR$3,570USD£2,773GBP
- Report
- October 2022
- 188 Pages
Global
From €3307EUR$3,570USD£2,773GBP
- Report
- July 2022
- 234 Pages
Global
From €3307EUR$3,570USD£2,773GBP
- Report
- February 2022
- 227 Pages
Global
From €3438EUR$3,712USD£2,884GBP
- Report
- August 2024
- 200 Pages
Global
From €4630EUR$4,999USD£3,884GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3704EUR$3,999USD£3,107GBP
- Report
- February 2024
- 160 Pages
Global
From €5093EUR$5,499USD£4,272GBP
- Report
- November 2023
- 140 Pages
Global
From €2778EUR$2,999USD£2,330GBP
- Report
- June 2023
- 140 Pages
Global
From €5556EUR$5,999USD£4,661GBP
- Report
- April 2023
- 160 Pages
Global
From €5556EUR$5,999USD£4,661GBP
- Book
- March 2024
- 496 Pages
- Book
- May 2023
- 512 Pages
- Book
- April 2023
- 2000 Pages
- Book
- August 2022
- 320 Pages
- Book
- June 2022
- 496 Pages
- Book
- April 2020
- 320 Pages
T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more